Dr. Reddy's Laboratories has licensed the Generx gene-therapy heart drug now in Phase III trials from U.S.-based Taxus Cardium Pharmaceuticals Group for the Myanmar, Russia, Vietnam and other markets. Financial arrangements for the deal were not disclosed.
Shares of Regulus spiked 10% Tuesday afternoon after its Big Pharma partner AstraZeneca stepped up to grab rights to a preclinical drug candidate for NASH with plans to steer it into clinical studies.
VBI Vaccines announced Monday that it is collaborating with Sanofi's vaccines unit to apply its Lipid Particle Vaccine to improve the stability of an undisclosed Sanofi Pasteur candidate. The terms of the agreement were not disclosed.
Working on a new initiative to move drugs out of discovery and into the clinic, Sanford-Burnham Medical Research Institute has struck a deal with Daiichi Sankyo to advance a new cardio drug into human studies.
Merck has partnered up with fast-moving upstart Arvinas to get its hands on technology that promises to give drug developers a crack at some previously untouchable targets, using the body's natural garbage system to dump troublesome proteins.
Nasdaq-listed Cytori Therapeutics said its exclusive licensee, Lorem Vascular, has been granted regulatory clearance for the Cytori Celution System by the China Food and Drug Administration, triggering a "substantial 2015 product purchase order for Cytori from Lorem Vascular."
Bristol-Myers Squibb is the latest pharma heavyweight to buy into gene therapy's renaissance, signing a deal with uniQure worth as much as $1 billion and getting its hands a novel cardiovascular treatment.
Japan's Kaken Pharmaceutical and U.S.-based Brickell Biotech signed a license agreement for exclusive rights to develop, commercialize and manufacture the Miami-based firm's investigational compound BBI-4000 in Japan and other Asian countries for the treatment of hyperhidrosis.
Samsung Pharmaceutical will manufacture and sell GemVax & KAEL Co. pancreatic cancer vaccine Riavax in South Korea.
Astellas Pharma has optioned the rights to be the first to negotiate global exclusive research-and-develop rights for a leukemia drug the University of Texas is set to test in early-stage trials in the United States. In return, Astellas is to provide $26 million in funding through two Phase I stages.